Physician

Reza Iranmanesh, MD

According to 2025 Medicare claims, Reza Iranmanesh, MD (NPI: 1689600363) practices ophthalmology in the Salinas, CA market, with the plurality of this provider's patient population coming from Monterey, CA. This provider's primary affiliated billing organization is VANTAGE EYE CENTER A MEDICAL CORP (NPI: 1588765903; TIN: 94-2720020) and primary practice location at 93940-5736.

Iranmanesh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,353 traditional Medicare patients, billed 10,186 HCPCS/CPT codes, and received $1,930,509 in Medicare payments. The top billing code was 92014 (Established patient complete exam of visual system). Part D data shows 135 prescription claims across 46 beneficiaries totaling $6,781 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 2 records totaling $150. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $812,735 to $1,930,509. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$965K$1.9M2015 Medicare payment: $812,735 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $882,462 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,003,859 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,068,321 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,059,510 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,318,560 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,383,687 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,537,741 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,683,953 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,930,509 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20152,1819,612$812,735
20162,1039,891$882,462
20171,87710,160$1,003,859
20181,7659,559$1,068,321
20191,4738,207$1,059,510
20201,2938,256$1,318,560
20211,3838,359$1,383,687
20221,3828,730$1,537,741
20231,3959,039$1,683,953
20241,35310,186$1,930,509

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$15K$31K2015 Drug cost: $17,463 (USD; Tot_Drug_Cst)2016 Drug cost: $30,864 (USD; Tot_Drug_Cst)2017 Drug cost: $29,730 (USD; Tot_Drug_Cst)2018 Drug cost: $29,428 (USD; Tot_Drug_Cst)2019 Drug cost: $25,802 (USD; Tot_Drug_Cst)2020 Drug cost: $30,670 (USD; Tot_Drug_Cst)2021 Drug cost: $17,401 (USD; Tot_Drug_Cst)2022 Drug cost: $21,598 (USD; Tot_Drug_Cst)2023 Drug cost: $18,486 (USD; Tot_Drug_Cst)2024 Drug cost: $6,781 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201581190$17,463
201671178$30,864
201770175$29,730
201863146$29,428
201966158$25,802
202056136$30,670
202145114$17,401
202259117$21,598
202363132$18,486
202446135$6,781

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
92014Established patient complete exam of visual system1,0101,329$93
67028Injection of drug into eye2361,238$90
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more365760$76
92012Established patient problem focused exam of visual system341722$62
92134Imaging of retina1,2932,739$32

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate442,285$2,493
Timolol MaleateTimolol Maleate221,170$279
LatanoprostLatanoprost171,285$259

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.2$150Regeneron Healthcare Solutions, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Reza Iranmanesh, MD?

Tedicare shows public-source Medicare data for Reza Iranmanesh, MD (NPI 1689600363), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Reza Iranmanesh, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Reza Iranmanesh, MD?

Reza Iranmanesh, MD is linked to VANTAGE EYE CENTER A MEDICAL CORP (billing NPI 1588765903) in the available physician profile data.

Does Reza Iranmanesh, MD have Open Payments data?

Reza Iranmanesh, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.